Chelsea Therapeutics upcoming data could boost stock, says Roth Capital
Roth Capital believes there is a 75% chance that the Phase 3 study of Chelsea's Droxidopa for hypertension will yield positive results next month The firm thinks the stock could rise to $7+ on positive results and it maintains a Buy rating on the shares. :theflyonthewall.com
News For CHTP From The Last 14 Days
Check below for free stories on CHTP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
